ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,219,072 | +273.2% | 2,264,359 | +429.3% | 0.01% | +333.3% |
| Q2 2023 | $594,631 | +140.5% | 427,792 | +175.1% | 0.00% | +50.0% |
| Q1 2023 | $247,250 | -72.8% | 155,503 | +6.5% | 0.00% | -66.7% |
| Q4 2022 | $909,699 | -0.3% | 146,019 | +316.3% | 0.01% | -25.0% |
| Q4 2020 | $912,000 | -29.8% | 35,072 | +0.3% | 0.01% | -38.5% |
| Q3 2020 | $1,299,000 | -34.5% | 34,952 | -9.5% | 0.01% | -38.1% |
| Q2 2020 | $1,982,000 | +64.8% | 38,620 | +1.2% | 0.02% | +40.0% |
| Q1 2020 | $1,203,000 | -51.1% | 38,159 | -7.5% | 0.02% | -37.5% |
| Q4 2019 | $2,460,000 | +107.8% | 41,247 | +27.7% | 0.02% | +60.0% |
| Q3 2019 | $1,184,000 | -18.0% | 32,310 | +4.1% | 0.02% | -25.0% |
| Q2 2019 | $1,444,000 | +13.3% | 31,050 | -2.1% | 0.02% | +11.1% |
| Q1 2019 | $1,274,000 | +239.7% | 31,720 | +289.2% | 0.02% | +157.1% |
| Q4 2018 | $375,000 | +7.8% | 8,150 | +3.8% | 0.01% | +40.0% |
| Q3 2018 | $348,000 | +11.2% | 7,850 | -57.6% | 0.01% | -28.6% |
| Q1 2016 | $313,000 | – | 18,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |